📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 15:36
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Nil Revenue in Q1 FY27; Vista Pharma Faces NPA Status and Going Concern Uncertainty
Vista Pharmaceuticals reported zero revenue from operations for the quarter ended June 30, 2026, compared to Rs 1.52 crore in the same period last year. The company posted a net loss of Rs 98.59 lakhs, marking its sixth consecutive year of losses. Lenders have classified the company's credit facilities as Non-Performing Assets (NPAs) due to defaults exceeding 90 days, resulting in frozen working capital accounts. Management is banking on a pending Rs 9.22 crore warrant conversion due by September 15, 2026, to sustain operations and negotiate debt restructuring.
Confidence: HIGH
What changedThe company has transitioned from minimal revenue to zero operational revenue, and its debt has been officially classified as NPA, creating a severe liquidity crunch.
Why it mattersThe business is facing a material uncertainty regarding its ability to continue as a going concern, with frozen bank accounts and significant unpaid statutory liabilities.
Revenue from Operations: NilNet Loss (Q1 FY27): Rs 98.59 LakhsNegative Working Capital: Rs 1.83 CrWarrant Money Due (by Sept 15): Rs 9.22 CrWarrant Money vs Market Cap: ~22%Unpaid Provident Fund: Rs 33.15 Lakhs
📅 Short termThe outlook is highly negative due to the lack of operational revenue and the NPA classification, which severely restricts business activity.
📈 Long termThe company's long-term survival is at risk; structural recovery depends entirely on successful debt restructuring and fresh capital infusion.
⚠ Risk flags
- NPA classification by lenders
- Going concern uncertainty
- Zero operational revenue
- Unpaid statutory liabilities
- Negative working capital
Key Highlights
Revenue from operations dropped to Nil from Rs 1.52 crore in the previous year's corresponding quarter.
Credit facilities classified as NPA by lenders, leading to a freeze on all working capital accounts.
Current liabilities exceed current assets by Rs 1.83 crore, with a net loss reported for the sixth consecutive year.
Outstanding statutory dues include Rs 33.15 lakhs in unpaid Provident Fund and Rs 7.16 lakhs in TDS.
Management expects Rs 9.22 crore in warrant call money by September 15, 2026, to meet operational obligations.
👀 What to Watch
Investors should closely monitor whether the company successfully collects the Rs 9.22 crore warrant subscription money by the September 15, 2026 deadline, as this is critical for its survival.
Vista Pharma Reports Nil Revenue and Rs 0.99 Cr Loss; Credit Facilities Classified as NPA
Vista Pharmaceuticals reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 1.52 Cr in the previous year's corresponding quarter. The company posted a net loss of Rs 0.99 Cr, marking its sixth consecutive year of losses. Critically, its credit facilities have been classified as Non-Performing Assets (NPAs) by lenders due to debt servicing defaults exceeding 90 days, resulting in frozen working capital accounts. The company's survival depends on receiving Rs 9.22 Cr in warrant call money due by September 15, 2026.
Confidence: HIGH
What changedThe company's financial distress has escalated from low revenue to zero revenue, and its debt has been officially classified as NPA, severely constraining operational liquidity.
Why it mattersThe classification as an NPA and zero revenue indicate severe operational and financial failure; the company's ability to continue as a going concern is now under material uncertainty.
Revenue (Q1 FY27): NilNet Loss (Q1 FY27): Rs 98.59 LakhsWarrant Call Money Expected: Rs 922.49 LakhsWorking Capital Deficit: Rs 183.32 LakhsUnpaid PF Dues: Rs 33.15 Lakhs
📅 Short termThe outlook is extremely negative in the short term due to the NPA status and lack of operational revenue, with all eyes on the mid-September funding deadline.
📈 Long termThe long-term viability is highly questionable given six consecutive years of losses and current structural defaults on debt and statutory payments.
⚠ Risk flags
- NPA classification by lenders
- Zero operational revenue
- Material uncertainty on going concern
- Default on statutory dues (PF, TDS)
- Negative working capital
Key Highlights
Revenue from operations dropped to Nil for the quarter compared to Rs 1.52 Cr in June 2025.
Net loss for the quarter stood at Rs 0.99 Cr, contributing to a negative working capital of Rs 1.83 Cr.
Credit facilities classified as NPA by lenders, leading to a freeze on all working capital accounts.
Outstanding statutory liabilities include Rs 33.15 lakh in Provident Fund and Rs 7.16 lakh in TDS.
Management is awaiting Rs 9.22 Cr in warrant subscription money due before September 15, 2026, to sustain operations.
👀 What to Watch
Investors should closely monitor whether the company successfully collects the Rs 9.22 Cr warrant call money by the September 15, 2026 deadline, as this is critical for its 'going concern' status.
